The incidence of metastatic prostate cancers at diagnosis increased as prostate-specific antigen (PSA) screenings across U.S. states decreased, registry data show. Between 2008 and 2016, the age-adjusted overall mean percentage of prostate cancers that were
Drop in PSA Screening, Increase in Metastatic Prostate Cancers
